Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84.
In a double-blind study of influenza in a population of college students in 1984, ribavirin small-particle aerosol treatment of 38 patients (18 treated, 20 control) infected with a new antigenic variant, influenza virus strain A/Victoria/7/83 (H1N1), was associated with statistically significant reductions in the height and duration of fever, systemic symptoms, and virus shedding. Patients received a total of 2.4 g of ribavirin over 42 h during 68 h of hospitalization without any side effects. In addition, in a study of patients infected with influenza virus strain B/Texas/1/84 (seven treated, eight control) treated with ribavirin aerosol showed a trend of more rapid recovery than control patients.
D000336:Aerosols; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006400:Hematocrit; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype; D009980:Influenza A virus; D009981:Influenza B virus; D007251:Influenza, Human / Q000188:drug therapy* / Q000382:microbiology; D007958:Leukocyte Count; D008297:Male; D011897:Random Allocation; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use*; D012263:Ribonucleosides / Q000627:therapeutic use*
D000336:Aerosols; D012263:Ribonucleosides; D012254:Ribavirin